Valneva SE
World Trade Center Lyon, Tour Oxygène
10-12 boulevard Marius Vivier Merle
Lyon
69003
France
Tel: 33-4-78-76-61-01
Website: http://www.valneva.com/
About Valneva SE
Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.LEADERSHIP:
CEO: Thomas Lingelbach
CFO: Reinhard Kandera
19 articles with Valneva SE
-
Clinical Catch-Up: January 25-29
2/1/2021
It was a busy week for clinical trial news. Read on for more information. -
BioSpace Movers & Shakers, Jan. 15
1/15/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers. -
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
-
It’s been a busy day so far for biopharma news and updates. Read on for more.
-
Check out some news happening today around the biopharma industry.
-
Clinical Catch-Up: October 19-23
10/26/2020
It was another busy week for clinical trial updates and news. Here’s a look. -
BioSpace Global Roundup, Sept. 17
9/17/2020
Companies from across the globe provide updates on their businesses and pipelines. -
Valneva and Dynavax Announce Commercial Supply Agreement for Inactivated, Adjuvanted COVID-19 Vaccine
9/14/2020
Dynavax will provide CpG 1018 to produce up to 190 million doses over a five year period to support Valneva's contract with the U.K. government
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
-
BioSpace Movers & Shakers, Aug. 7
8/7/2020
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers. -
CORRECTING and REPLACING CDC Publishes Updated Recommendations for Valneva’s Japanese Encephalitis Vaccine IXIARO®
7/29/2019
ACIP Guidelines Recommend Vaccination for All Longer-Term U.S. Travelers to JE-Endemic Countries; Shorter-Term Travelers Should Also Consider Vaccination
-
Valneva Receives FDA Approval for Accelerated Vaccine Dosing Schedule for IXIARO®
10/5/2018
Valneva USA, the U.S. subsidiary of global vaccine biotech company Valneva SE, today announced Food and Drug Administration (FDA) approval of an accelerated dosing regimen for IXIARO® (Japanese Encephalitis Vaccine, Inactivated, Adsorbed), the only vaccine approved in the United States indicated for protection against disease caused by Japanese encephalitis (JE) virus.
-
VALNEVA Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
2/15/2018
Total revenues of €109.8 million in 2017 (2016 - €97.9 million) representing year-on-year growth of 12%.
-
VALNEVA Expands its Commercial Operations and Establishes U.S. Infrastructure
12/1/2017
The fully-owned commercial subsidiary will take direct control of sales and marketing of IXIARO in the U.S. private market with the aim of accelerating sales growth of the vaccine.
-
VALNEVA Reports Strong Operational Performance for the First Nine Months of 2017
11/9/2017
Total revenues of €79.8 million in the first nine months 2017 compared to €70.7 million in the first nine months of 2016 benefiting from a 20% year-on-year growth in product sales.
-
VALNEVA Signs $39.6M IXIARO Supply Contract With U.S. Government
11/8/2017
The new agreement will supplement the initial contract Valneva signed with the US military in March 2016 as the maximum quantity of doses allowed in the precedent contract was reached earlier than expected.
-
Valneva: Reports Robust H1 2017 Financial Results & Major R&D Progress
8/31/2017